Aaron Gerds

Employment

• Cleveland Clinic Assitant Professor
  2013 - Present
• Fred Hutchinson Cancer Research Center Senior Fellow
  2012 - 2013

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (193)

• A phase 1 study of VAC85135, a neoantigen vaccine regimen targeting calreticulin and JAK2 mutations, in combination with ipilimumab in patients with myeloproliferative neoplasms
  Cancer Immunology, Immunotherapy 2026 DOI: 10.1007/s00262-026-04507-8
  +Save
• Sapablursen for Erythrocytosis Control in Patients with Polycythemia Vera
  Blood Journal 2026 DOI: 10.1182/blood.2026033792
  +Save
• The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study
  Blood Advances 2026 DOI: 10.1182/bloodadvances.2025018141
  +Save
• Disease Burden, Inadequate Hematocrit Control, and Thromboembolic Events in Patients with Polycythemia Vera Despite Current Standard of Care Treatment: A Retrospective Claims Study
  Journal of Blood Medicine 2026 DOI: 10.2147/JBM.S626464
  +Save
• Supplementary Figure S1 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
  2025 DOI: 10.1158/1078-0432.30709681
  +Save
• Supplementary Figure S2 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
  2025 DOI: 10.1158/1078-0432.30709678
  +Save
• Supplementary Figure S3 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
  2025 DOI: 10.1158/1078-0432.30709675
  +Save
• Supplementary Figure S4 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
  2025 DOI: 10.1158/1078-0432.30709672
  +Save
• Supplementary Figure S5 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
  2025 DOI: 10.1158/1078-0432.30709669
  +Save
• Supplementary Figure S6 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
  2025 DOI: 10.1158/1078-0432.30709666
  +Save